RxDoctor Payments Data

Martha Reilley

Nurse Practitioner · Annapolis, MDNPI 1003381997

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 802 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,979in general payments, 2019–2025

Across 802 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Harmony Biosciences LLC$2K
  • Insmed, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • plus $9K from 34 others

What the payments were for

  • Food & beverage$17,54198%
  • Education$4212%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,979 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter145$184,569
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$62,707
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr48$40,899
Spiriva RespimatTiotropium Bromide36$32,162
Breo ElliptaFluticasone/Vilanterol47$31,136
SymbicortBudesonide/Formoterol Fumarate12$3,580
Albuterol Sulfate HfaAlbuterol Sulfate129$3,574
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,851
Wixela InhubFluticasone Propion/Salmeterol16$2,650
Azelastine Hcl46$1,634
Azithromycin52$1,440
Ventolin HfaAlbuterol Sulfate17$976
Montelukast Sodium23$681
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$511
Fluticasone Propionate30$437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,811$256,603240 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,426$66,28787 claims
Boehringer IngelheimSpiriva Respimat$717$32,16236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →